Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study
Bristol-Myers Squibb
Summary
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participants ≥18 years of age. * Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy * Provided informed consent to participate in the study Exclusion Criteria: * Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors * Treated for \>7 days with mavacamten by the day of completing the baseline survey * Enrolled in any clinical trials at the time of or within the six-month period prior to the screening * Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the…
Interventions
- DrugMavacamten
As prescribed by treating physician
Location
- Analysis Group Inc.Boston, Massachusetts